downgrad neutral revis forecast await
action revis forecast ono introduc
estim lower outlook onward reflect greater-than-
opdivo
administration/dosag result price reduct
even reduc earn outlook still consist
scenario sustain sale profit growth howev think share
price upsid remain limit given headwind market focu
opdivo accordingli downgrad ono outperform neutral
cut target price potenti return
novemb chang
invest overview look opdivo-driven earn trend solidli
due support rise oversea royalti bristol-my squibb
merck expans indic japan sale growth
hamper string drug price reduct ono expect
cost-effect adjust expect
subsequ reduct market growth similar adjust sale
reach level said media report invent
patent right issu japan us weigh share price
opdivo innov develop japan look current
august
catalysts/risk opdivo sale could continu grow drug continu
gain approv new adjuv neoadjuv indic although
invent right issu japan impact sale present
question issu resolv interest simpli
parti tasuku honjo distinguish professor kyoto univers
winner nobel prize medicin
valuat base target price forward price-to-earnings
prev appli ep forecast
valuat metric
chang tp
number share mn
price month
outperform neutral
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price may upsid rate outperform neutral target price
profit tax
issuanc retir stock
net chang cash
number share mn
incom expens
profit tax
cash equival
royalti bm
compani mention price
